• Explore /
  • Poster
  • / A randomized phase II neoadjuvant study (GeparNuevo) to investigate the addition of durvalumab, a PD-L1 antibody, to a taxane-anthracycline containing chemotherapy in triple negative breast cancer (TNBC).

A randomized phase II neoadjuvant study (GeparNuevo) to investigate the addition of durvalumab, a PD-L1 antibody, to a taxane-anthracycline containing chemotherapy in triple negative breast cancer (TNBC).

Abstract Poster

Authors

Sibylle Loibl

Sibylle Loibl

German Breast Group, Neu-Isenburg, Germany

Sibylle Loibl , Michael Untch , Nicole Burchardi , Jens Bodo Huober , Jens Uwe Blohmer , Eva-Maria Grischke , Jenny Furlanetto , Hans Tesch , Claus Hanusch , Mahdi Rezai , Christian Jackisch , Wolfgang D Schmitt , Gunter Von Minckwitz , Jörg Thomalla , Sherko Kummel , Beate Rautenberg , Peter A. Fasching , Kerstin Rhiem , Carsten Denkert , Andreas Schneeweiss

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2017 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Developmental Therapeutics—Immunotherapy

Track

Developmental Therapeutics and Translational Research,Immunotherapy

Sub Track

Immune Checkpoint Inhibitors

Clinical Trial Registration Number

NCT02685059

Citation

J Clin Oncol 35, 2017 (suppl; abstr 3062)

DOI

10.1200/JCO.2017.35.15_suppl.3062

Abstract #

3062

Poster Bd #

157

Abstract Disclosures

Similar Posters

First Author: Kenji Higaki

First Author: Ignacio Ortego

First Author: Shigehira Saji

First Author: Renske Kornalijnslijper-Altena